NJ-EXPERIC
Experic, a contract development and manufacturing organization (CDMO) and clinical trial supply services company serving the biopharmaceutical industry, announced its new facility in Dublin, Ireland, to support global clinical trials. The opening of this depot will expand the Company’s global footprint, increase the efficiency of its worldwide clinical trial supply services, and facilitate future growth.
At the forefront of this expansion effort is Experic's Vice President of Operations, Brian Fagan. "Experic is a company that listens to its customers,” shared the 25+ year clinical trial supply veteran. “When customers voiced their preference for more clinical trial supply services under the Experic umbrella – we listened - and made it a strategic priority to expand direct management of these services in Europe.”
The new Experic depot will do just that thanks to its geographical proximity to European markets and North America. The secure, 10,000 sq. ft. warehouse space will provide monitored storage and logistics services, including cold storage and re-labeling capabilities, for the rapid and reliable distribution of Investigational Medicinal Products (IMPs) and comparators for pharmaceutical companies conducting global clinical trials with investigator sites and patients across Europe. Opening in the second half of 2024, the depot activities will be carried out by local talent that is familiar with EU regulatory requirements, with the support of Experic’s expert project management team in the United States and the Company’s current Global Partner Depot Network.
This facility serves as the company's first physical expansion of business into the EU and will ultimately contribute to the efficiency and success of trial services.
If you would like to request a meeting with Experic at Clinical Trial Supply Europe in Barcelona next month, please go here.
About Experic:
Experic, a contract development and manufacturing organization (CDMO) and clinical trial supply services company, supports every phase of a product’s life cycle from conception to clinical and commercial scale, across a range of dosing and packaging formats. From our state-of-the-art, cGMP facility, we manage global delivery of the highest quality products, even for expedited projects, while providing unparalleled knowledge, expertise, and customer service. Learn more about our manufacturing and clinical trial supply services at expericservices.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240227449218/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Restylane® Lyft™ for the Enhancement of the Chin Profile5.11.2025 07:00:00 CET | Press release
This approval is based on results showing the safety and effectiveness of Restylane Lyft in enhancing the chin profile, with high patient satisfaction and long-lasting results1,2 Restylane Lyft is the only hyaluronic acid (HA) injectable approved to treat the midface, facial folds and wrinkles, back of hands and the chin, with consistent results observed across diverse patient types1,2 Galderma’s Restylane portfolio, including Restylane Lyft, is supported by decades of clinical evidence and real patient experiences with over 77 million treatments delivered worldwide3,4 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Restylane Lyft with Lidocainefor augmentation of the chin region to improve the chin profile in patients over the age of 21 with mild-to-moderate chin retrusion.2 Restylane Lyft is a versatile HA injectable with over 20 years of worldwide safety data, which is also
The Estée Lauder Companies Announces Pricing of Secondary Offering of Class A Common Stock by Selling Stockholders5.11.2025 02:08:00 CET | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announces the pricing of the previously announced registered public offering (the “Offering”) of the Company’s Class A Common Stock, par value $.01 per share, by trusts affiliated with descendants of Leonard A. Lauder (the “Selling Stockholders”) at a price to the public of $90 per share. The Selling Stockholders will receive all of the proceeds from the Offering. The Company is not selling any shares of Class A Common Stock in the Offering and will not receive any proceeds from the Offering. The Offering is expected to close on November 6, 2025, subject to the satisfaction of customary closing conditions. The Selling Stockholders intend to use the proceeds of the Offering to assist with the settlement of Leonard A. Lauder’s estate, including to satisfy certain estate obligations such as estate taxes, debts and administration expenses. Based on shares outstanding as of October 23, 2025, following completion of the offering, members of th
The Earthshot Prize and 500 Global Announce Strategic Partnership to Advance Climate Innovation in Emerging Markets5.11.2025 01:01:00 CET | Press release
500 Global and The Earthshot Prize are partnering on an investment strategy to identify, support and scale climate solutions across Emerging Markets.Supporting three themes at the intersection of climate impact and commercial viability: AgTech, Clean Tech, and Nature Tech.The strategy was announced at The Earthshot Prize Summit in Rio De Janeiro ahead of the 2025 Earthshot Prize Awards Night, targeting to roll out H1 of 2026. 500 Global, one of the world’s most active venture capital firms and The Earthshot Prize, the world’s most prestigious and impactful environmental award, are announcing today a new strategic partnership to accelerate climate innovation in Emerging Markets, as climate finance is more relevant than ever before. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251104586243/en/ 500 Global intends to develop and implement an investment strategy designed to de-risk early-stage investments, unlocking private cap
Cooler Master Announces the QUBE 540 PC Case, a Compact Size with Unlimited Creativity4.11.2025 23:58:00 CET | Press release
Designed for Creators, Gamers, and DIY Builders Cooler Master, a global leader in PC components and tech lifestyle solutions, today announced the QUBE 540, a compact case for today. The QUBE 540 offers orientation flexibility, so you can build a vertical or horizontal system that fits your desk or shelf. Inside, a modular interior lets you tailor the layout to your components and airflow preferences. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251104224092/en/ The QUBE 540 (Stardust Iron) with 3D-printed additions holding headphones and keyboard. The QUBE 540 keeps the clean, geometric design language of the QUBE series while raising the bar on practical adaptability. It fits comfortably in limited spaces such as small apartments and dorm rooms, and it looks at home in creator studios and living areas. The case ships in two colors, Moonstone or Stardust Iron, giving users options that blend with modern setups and room aes
IFF Reports Third Quarter 2025 Results4.11.2025 23:12:00 CET | Press release
Reaffirms Full Year 2025 Financial Guidance IFF (NYSE: IFF) reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Consolidated Summary: Management Commentary “Our third quarter results demonstrate continued execution in a tough operating environment,” said Erik Fyrwald, CEO of IFF. “Sales momentum in Scent and Taste remain solid, supported by strong new win contributions. This performance helped offset short-term pressures in Health and Biosciences - which we are addressing by strengthening our innovation and commercial capabilities - and a sales reduction in Food Ingredients as we focus on driving higher margins.” “Profitability in the quarter improved high-single digits year-over-year, with margin expansion driven predominantly by productivity. By maintaining a disciplined focus on operational excellence, we are driving sustained profitability while investing in IFF for long-term success.” “In a more challenging environment, we’re doing what we
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom